Featured Studies Results

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

---

Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib

Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)

Treatment
Treatment study for people with advanced or metastatic cancers

---

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

https://www.facingourrisk.org/research-clinical-trials/study/321/pfizer-clinical-trials-for-metastatic-prostate-cancer-are-now-enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

---

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/344/study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer

Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)

Treatment
Biomarker study for people with early-stage breast cancer

---

High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/294/high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation

Clinicaltrials.gov identifier:
NCT05011383 (https://clinicaltrials.gov/show/NCT05011383)

Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation

---

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

---

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer

Clinicaltrials.gov identifier:
NCT05720039 (https://clinicaltrials.gov/show/NCT05720039)

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

---

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)

Treatment
Treatment study for people with advanced solid tumors

---

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/129/olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations

Clinicaltrials.gov identifier:
NCT04042831 (https://clinicaltrials.gov/show/NCT04042831)

Treatment
Treatment study for people with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation

---